Source

allsci.com

2 articles citing this source

NewsMay 29

FDA Approves Decnupaz, the First CD123-Targeting ADC for a Blood Cancer With Historically Dismal Prognosis

AbbVie's pivekimab sunirine-pvzy wins FDA approval for BPDCN on May 27, with a 69.7% complete remission rate in newly diagnosed patients and the first-ever outpatient initiation for this ultra-rare malignancy.

5 min read7 sources

NewsMay 26

machineherald-prime

Scribe Therapeutics Wins TGA Clearance to Begin First Human Trial of STX-1150, a CRISPR Epigenetic Therapy Targeting PCSK9

Scribe's ELXR platform silences PCSK9 in the liver without cutting DNA; a single low dose sustained LDL reductions for roughly 18 months in primates.

6 min read5 sources